Clinical trial of Tagar Tablet in Hypertension.

Randomized controlled clinical trial to evaluate an add on effect of Tagar Vati in the management of Essential Hypertension. - NIL

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/03/064721

Enrollment

Registered

2024-03-22

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients having Stage I hypertension, isolated systolic and isolated diastolic hypertension. 2. Patients who is known case of Hypertension but not suffering from more than 10 years. Also known case of hypertension with or without antihypertensive. 3. Shirashool, Bhrama, Klama, Hridspandana, Anidra, Swedadhikya ,Shwaskashtata patient having these symptoms of Hypertension will be included in the clinical study . 4. Patients in between 20 to 60 years of age. 5. Patients having serum creatinine level less than 1.5 mg/dl. 6. Patients with raised blood pressure with Beta blocker.

Exclusion criteria

Exclusion criteria: 1. Patients having Stage II, stage III and above known case of hypertension will be excluded. 2. Pregnant women and lactating mothers. 3. Patient suffering from any other serious systemic illness like cerebrovascular diseases, Acute Haemorrhagic conditions, Acute septic shock etc.

Design outcomes

Primary

Measure	Time frame
1.Blood pressure monitoring 2.Serum creatinine 3.Lipid Profile 4. ECGTimepoint: At base line, 15 days and 30 days	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr Vidya Rajendra Jatti

MAMS Sumatibhai Shah Ayurved College Hdapsar Pune

vidyajatti06@gmail.com9373692663

Outcome results